Prot #APL2-C3G‐310: A Phase 3, Randomized, Placebo‐Controlled, Double‐Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune‐Complex Membranoproliferative Glomerulonephritis

Project: Research project

Project Details

StatusActive
Effective start/end date9/25/23 → 9/25/26

Funding

  • Worldwide Clinical Trials, Inc. (Prot #APL2 C3G-310 // Prot #APL2 C3G-310)
  • Apellis Pharmaceuticals, Inc. (Prot #APL2 C3G-310 // Prot #APL2 C3G-310)